The report covers the forecast and analysis of the plasmid market on a global and regional level. The study provides historical data from 2015 to 2018 along with a forecast from 2019 to 2027 based on revenue (USD Million). The study includes drivers and restraints of the plasmid market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the plasmid market on a global level.
In order to give the users of this report a comprehensive view of the Telepathology service market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product &service launches, agreements, partnerships, collaborations &joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.
The study provides a decisive view of the plasmid market by segmenting the market based on the general type, specific plasmid types, applications, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2027. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Escalating awareness about the gene treatment along with the acceptance of gene therapy for treating chronic diseases like Alzheimer's and attention deficit hyperactivity will magnify the market surge over the forecast timeline. Moreover, gene therapy has a high potential for treating genetic disorders, as well as chronic ailments like cancer, and this will further enhance business expansion over the forecast timespan. Nonetheless, mutagenesis coupled with high costs related to gene treatment can act as an inhibiting factor for the plasmid industry over the period from 2019 to 2027.
Based on the general type, the market is divided into Conjugative and Non-Conjugative. On the basis of specific plasmid types, the industry is classified into F-Plasmids, Col Plasmids, Resistance Plasmids, Cryptic Plasmids, Degradative Plasmids, and Virulence Plasmids. Application-wise, the market is sectored into Transfection, Recombinant DNA Technology, Gene Therapy, and Others.
Key players involved in the plasmid industry include Aldevron, GenScript, PlasmidFactory GmbH & Co. KG, VGXI, Inc., Oxford Genetics Ltd., Applied StemCell, Altogen Biosystems, Cobra Biologics, Copernicus Therapeutics, Inc., Takara Bio Inc., InvivoGen, Miltenyi Biotec, Medigene Sdn Bhd, MaxCyte, Inc., Mirus Bio LLC, MolMed S.p.A., GenePharma, and Polyplus Transfection.
Table of Content
Industry Major Market Players